Danaher Corporation (DHR)
Danaher beats Q2 profit estimates on strength in medical testing business
Danaher beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its genetic testing services, sending shares of the life sciences firm up nearly 8% in premarket trading.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher Q2: Inventory Overhang, But Low Expectations Limit Downside
Danaher Corporation stock saw a high single-digit percentage increase from April to mid-June, but has since given up most of the gains. Concerns about inventory destocking in the bioprocessing market have impacted investor sentiment, but expectations are already priced in. Despite short-term challenges, Danaher's medium to long-term prospects remain positive, with good growth starting FY25.
Danaher (DHR) Gears Up to Post Q2 Earnings: What to Expect
Danaher's (DHR) second-quarter earnings are likely to be aided by strength in the Diagnostics and Life Sciences segment.
Danaher (DHR) Upgraded to Buy: Here's What You Should Know
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Danaher (DHR) Stock Outpacing Its Conglomerates Peers This Year?
Here is how Danaher (DHR) and Honeywell International Inc. (HON) have performed compared to their sector so far this year.
Here's Why Hold Strategy Is Apt for Danaher (DHR) Stock Now
Strength in the Life Sciences segment augurs well for Danaher (DHR). The company's measures to reward its shareholders are promising.
Why Is Danaher (DHR) Up 6.7% Since Last Earnings Report?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
